C4 Therapeutics Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
110
- Stock Symbol
-
CCCC
- Share Price
-
$1.54
- (As of Friday Closing)
C4 Therapeutics General Information
Description
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
Contact Information
Website
www.c4therapeutics.comCorporate Office
- 490 Arsenal Way
- Suite 120
- Watertown, MA 02472
- United States
Corporate Office
- 490 Arsenal Way
- Suite 120
- Watertown, MA 02472
- United States
C4 Therapeutics Stock Performance
As of 25-Apr-2025, C4 Therapeutics’s stock price is $1.54. Its current market cap is $114M with 71M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.54 | $1.61 | $1.08 - $7.66 | $114M | 71M | 1.39M | -$1.52 |
C4 Therapeutics Financials Summary
As of 31-Dec-2024, C4 Therapeutics has a trailing 12-month revenue of $35.6M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 65,574 | 65,574 | 134,051 | 63,248 |
| Revenue | 35,584 | 35,584 | 20,756 | 31,096 |
| EBITDA | (117,796) | (117,796) | (137,772) | (127,858) |
| Net Income | (105,316) | (105,316) | (132,493) | (128,175) |
| Total Assets | 349,602 | 349,602 | 376,451 | 430,840 |
| Total Debt | 65,756 | 65,756 | 70,976 | 87,152 |
C4 Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
C4 Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
C4 Therapeutics Comparisons
Industry
Financing
Details
C4 Therapeutics Competitors (7)
One of C4 Therapeutics’s 7 competitors is Arvinas, a Formerly VC-backed company based in New Haven, CT.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Arvinas | Formerly VC-backed | New Haven, CT | ||||
| Kymera Therapeutics | Formerly VC-backed | Watertown, MA | ||||
| Monte Rosa Therapeutics | Formerly VC-backed | Boston, MA | ||||
| SAGE Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Voyager Therapeutics | Corporation | Lexington, MA |
C4 Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
C4 Therapeutics Patents
C4 Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023292503-A1 | Compounds for the targeted degradation of smarca2 | Pending | 15-Jun-2022 | ||
| US-20250121070-A1 | Compounds for the targeted degradation of smarca2 | Pending | 15-Jun-2022 | ||
| EP-4539849-A1 | Compounds for the targeted degradation of smarca2 | Pending | 15-Jun-2022 | ||
| AU-2023283735-A1 | Bicyclic-substituted glutarimide cereblon binders | Pending | 06-Jun-2022 | ||
| EP-4536656-A1 | Bicyclic-substituted glutarimide cereblon binders | Pending | 06-Jun-2022 | C07D413/04 |
C4 Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
C4 Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
C4 Therapeutics ESG
Risk Overview
Risk Rating
Updated May, 24, 2023
25.16 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,842
Rank
Percentile
Pharmaceuticals
Industry
of 898
Rank
Percentile
Biotechnology
Subindustry
of 402
Rank
Percentile
C4 Therapeutics FAQs
-
When was C4 Therapeutics founded?
C4 Therapeutics was founded in 2015.
-
Where is C4 Therapeutics headquartered?
C4 Therapeutics is headquartered in Watertown, MA.
-
What is the size of C4 Therapeutics?
C4 Therapeutics has 110 total employees.
-
What industry is C4 Therapeutics in?
C4 Therapeutics’s primary industry is Pharmaceuticals.
-
Is C4 Therapeutics a private or public company?
C4 Therapeutics is a Public company.
-
What is C4 Therapeutics’s stock symbol?
The ticker symbol for C4 Therapeutics is CCCC.
-
What is the current stock price of C4 Therapeutics?
As of 25-Apr-2025 the stock price of C4 Therapeutics is $1.54.
-
What is the current market cap of C4 Therapeutics?
The current market capitalization of C4 Therapeutics is $114M.
-
What is C4 Therapeutics’s current revenue?
The trailing twelve month revenue for C4 Therapeutics is $35.6M.
-
Who are C4 Therapeutics’s competitors?
Arvinas, Kymera Therapeutics, Monte Rosa Therapeutics, SAGE Therapeutics, and Voyager Therapeutics are some of the 7 competitors of C4 Therapeutics.
-
What is C4 Therapeutics’s annual earnings per share (EPS)?
C4 Therapeutics’s EPS for 12 months was -$1.52.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
